암젠(AMGN)는 NASDAQ에 상장된 Healthcare · Drug Manufacturers - General 기업입니다. 현재가 $385.65 (+1.55%), 시가총액 $179.05B, PER (주가수익비율) 23.09, 52주 최저~최고 $271.18 ~ $388.16.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma;
암젠의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
최근 토론 7건 · 강세 7 · 약세 0 · 중립 0.
암젠의 현재 주가는 $385.65 (+1.55%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
암젠의 시가총액은 약 $179.05B입니다. PER은 23.09입니다.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, an